Importantly, mTOR exists in two different complexes: mTORC1, which is the target for rapamycin and its analogues, and mTORC2, which activates AKT, thereby promoting feedback tumor cell proliferation and the development of resistance to mTORC1 inhibitors (mTORC1i) [8,9,10]. This evidence concerns the gene AKT1 and neoplasm.